{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:17:35Z","timestamp":1787735855212,"version":"build-2784847793"},"reference-count":63,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Translational oncology has moved rapidly from histopathology and single-analyte biomarkers toward multi-dimensional molecular profiling. Yet many clinically deployed tests still use reductionist biomarker strategies that under-represent cancer complexity. This review examines whether a mechanistic, multi-layered, and specimen-aware approach can improve cancer detection, classification, prognosis, minimal residual disease (MRD) assessment, and therapeutic selection. Evidence across solid tumours shows that genomic alterations alone incompletely explain tumour state, metastatic behaviour, immune evasion, or therapeutic vulnerability. Integrated genome and transcriptome analyses, proteogenomics, single-cell atlases, fragmentomic, methylation based cell-free DNA assays, metabolomics and microbiome assessments reveal clinically relevant biology that single modality tests cannot determine. Minimally invasive collected specimens can extend access to screening, diagnosis and longitudinal monitoring, but the choice of specimen should be matched to disease biology and analytes that represent mechanisms of oncogenesis. However, translation remains constrained by pre-analytical variability, contamination, differences in tumour shedding behaviour, clonal haematopoiesis, translation of generated models, incomplete external validation and uncertain downstream clinical utility for emerging platforms. This review provides a commentary on the future of cancer diagnostics, the considerations and barriers to clinical translation, the relationship between utility and dimensionality of biomarkers assessed and the emerging rationale towards mechanistically grounded integrated models.<\/jats:p>","DOI":"10.3390\/cancers18172766","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:11:15Z","timestamp":1787731875000},"page":"2766","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism-Driven Diagnostic Development: A Specimen-Aware Framework Illustrated by Colorectal Cancer and Solid Tumours"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-0812","authenticated-orcid":false,"given":"Ian","family":"Daniels","sequence":"first","affiliation":[{"name":"Origin Sciences and Granta Park, Cambridge CB21 6AD, Cambridgeshire, UK"},{"name":"Royal Devon University Healthcare NHS Foundation Trust, Barrack Road, Exeter EX53BJ, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-6062","authenticated-orcid":false,"given":"Andrew J.","family":"Page","sequence":"additional","affiliation":[{"name":"Origin Sciences and Granta Park, Cambridge CB21 6AD, Cambridgeshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wise","sequence":"additional","affiliation":[{"name":"Origin Sciences and Granta Park, Cambridge CB21 6AD, Cambridgeshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: Current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/2159-8290.CD-23-1194","article-title":"Precision Oncology: 2023 in Review","volume":"13","author":"Suehnholz","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e75181","DOI":"10.7554\/eLife.75181","article-title":"Cancer type classification using plasma cell-free RNAs derived from human and microbes","volume":"11","author":"Chen","year":"2022","journal-title":"eLife"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ccell.2024.07.005","article-title":"Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers","volume":"42","author":"Sun","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2139979","DOI":"10.1080\/19490976.2022.2139979","article-title":"Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer","volume":"14","author":"Bosch","year":"2022","journal-title":"Gut Microbes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014Implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","article-title":"Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities","volume":"177","author":"Vasaikar","year":"2019","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113810","DOI":"10.1016\/j.celrep.2024.113810","article-title":"Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures","volume":"43","author":"Tanaka","year":"2024","journal-title":"Cell Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12967-024-04984-4","article-title":"Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer","volume":"22","author":"Zou","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41586-024-07135-3","article-title":"SOX17 enables immune evasion of early colorectal adenomas and cancers","volume":"627","author":"Goto","year":"2024","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-024-07769-3","article-title":"Prognostic genome and transcriptome signatures in colorectal cancers","volume":"633","author":"Nunes","year":"2024","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25268","DOI":"10.1038\/s41598-025-08915-1","article-title":"Integrative analysis of multi-omics data and gut microbiota composition reveals prognostic subtypes and predicts immunotherapy response in colorectal cancer using machine learning","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41588-022-01088-x","article-title":"Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer","volume":"54","author":"Becker","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ccell.2025.03.018","article-title":"New horizons at the interface of artificial intelligence and translational cancer research","volume":"43","author":"Yates","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","article-title":"Colorectal cancer incidence trends in younger versus older adults: An analysis of population-based cancer registry data","volume":"26","author":"Sung","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_19","unstructured":"(2026, May 06). National Cancer Plan for England, Available online: https:\/\/assets.publishing.service.gov.uk\/media\/69dce11fd3e08b8871b6662c\/national-cancer-plan-for-england-delivering-world-class-cancer-care.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198809013190901","article-title":"Genetic alterations during colorectal-tumor development","volume":"319","author":"Vogelstein","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s43018-024-00841-x","article-title":"Recapitulating the adenoma-carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids","volume":"5","author":"Mizutani","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41586-024-08133-1","article-title":"Polyclonal-to-monoclonal transition in colorectal precancerous evolution","volume":"636","author":"Lu","year":"2024","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer","volume":"24","author":"Raez","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.annonc.2025.02.005","article-title":"CtDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma","volume":"36","author":"Lorca","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(20)31099-0","article-title":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett\u2019s oesophagus in a primary care setting: A multicentre, pragmatic, randomised controlled trial","volume":"396","author":"Fitzgerald","year":"2020","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100969","DOI":"10.1016\/j.eclinm.2021.100969","article-title":"Economic evaluation of Cytosponge\u00ae-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data","volume":"37","author":"Swart","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10876","DOI":"10.1038\/s41467-025-66006-1","article-title":"Hologenomic analysis of rectal mucus sampling for detection of adenomatous polyps and colorectal cancer","volume":"16","author":"Tock","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2021-324755","article-title":"A faecal microbiota signature with high specificity for pancreatic cancer","volume":"71","author":"Kartal","year":"2022","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, Y., Cheng, Y., Liu, W., Li, J., Li, S., Ma, T., Kwok, L.-Y., Cai, Z., and Sun, Z. (2026). Gut microbial and functional signatures in breast cancer: An integrated metagenomic and machine learning approach to non-invasive detection. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1722632"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41388-024-02974-w","article-title":"Robustness of cancer microbiome signals over a broad range of methodological variation","volume":"43","author":"McDonald","year":"2024","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41591-025-03693-9","article-title":"Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer","volume":"31","author":"Piccinno","year":"2025","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cell.2024.03.021","article-title":"A pan-cancer analysis of the microbiome in metastatic cancer","volume":"187","author":"Battaglia","year":"2024","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Salter, S.J., Cox, M.J., Turek, E.M., Calus, S.T., Cookson, W.O., Moffatt, M.F., Turner, P., Parkhill, J., Loman, N.J., and Walker, A.W. (2014). Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol., 12.","DOI":"10.1186\/s12915-014-0087-z"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eads6166","DOI":"10.1126\/scitranslmed.ads6166","article-title":"The landscape of microbial associations in human cancer","volume":"17","author":"Gihawi","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-018-0160-1","article-title":"Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography","volume":"24","author":"Deschasaux","year":"2018","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Abdill, R.J., Adamowicz, E.M., and Blekhman, R. (2022). Public human microbiome data are dominated by highly developed countries. PLoS Biol., 20.","DOI":"10.1371\/journal.pbio.3001536"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Savva, K.V., Kawka, M., Vadhwana, B., Penumaka, R., Patton, I., Khan, K., Perrott, C., Das, S., Giot, M., and Mavroveli, S. (2023). The Biomarker Toolkit\u2014An evidence-based guideline to predict cancer biomarker success and guide development. BMC Med., 21.","DOI":"10.1186\/s12916-023-03075-3"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Baggaley, A.E., Kabbani, J., Savva, K.V., Gogoi, P., Kinross, J.M., Ni, M.Z., and Peters, C.J. (2025). Assessing the translation of diagnostic colorectal cancer biomarkers from bench to bedside. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1598697"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Savva, K.V., MacKenzie, A., Coombes, R.C., Zhifang, N.M., Hanna, B.G., and Peters, C.J. (2024). An original study assessing biomarker success rate in breast cancer recurrence biomarker research. BMC Med., 22.","DOI":"10.1186\/s12916-024-03460-6"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","article-title":"Evaluation of cell-free DNA approaches for multi-cancer early detection","volume":"40","author":"Jamshidi","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): A prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","article-title":"Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): A large-scale, observational cohort study","volume":"24","author":"Nicholson","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-025-03735-2","article-title":"Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics","volume":"31","author":"Bao","year":"2025","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-024-00568-z","article-title":"A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening","volume":"8","author":"Vittone","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/jama.2023.22231","article-title":"Multitarget Stool RNA Test for Colorectal Cancer Screening","volume":"330","author":"Barnell","year":"2023","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-024-55428-y","article-title":"Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals","volume":"16","author":"Vavoulis","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_51","unstructured":"U.S. Food and Drug Administration (2023). FDA Executive Summary for the Molecular and Clinical Genetics Devices Panel: Multi-Cancer Detection In Vitro Diagnostic Devices, FDA."},{"key":"ref_52","unstructured":"National Cancer Institute (2025). The Vanguard Study on Multi-Cancer Detection Tests, NCI."},{"key":"ref_53","unstructured":"U.S. Food and Drug Administration (2024). Shield\u2014P230009, FDA."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa2304714","article-title":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","volume":"390","author":"Chung","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_55","unstructured":"Voss, A. (2026, May 04). Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit in? National Cancer Institute Cancer Currents Blog, Available online: https:\/\/prevention.cancer.gov\/news-and-events\/news\/colorectal-cancer-screening-where-does-shield-liquid-biopsy-fit."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2025.7515","article-title":"Clinical Validation of a Circulating Tumor DNA\u2013Based Blood Test to Screen for Colorectal Cancer","volume":"334","author":"Shaukat","year":"2025","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"q1706","DOI":"10.1136\/bmj.q1706","article-title":"Galleri promises to detect multiple cancers-but new evidence casts doubt on this much hyped blood test","volume":"386","author":"McCartney","year":"2024","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"s364","DOI":"10.1136\/bmj.s364","article-title":"Galleri cancer tests: Controversial NHS trial fails to meet key goal","volume":"392","author":"Cohen","year":"2026","journal-title":"BMJ"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2310336","article-title":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","volume":"390","author":"Imperiale","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/gutjnl-2020-321956","article-title":"Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: A diagnostic accuracy study","volume":"70","author":"Chen","year":"2021","journal-title":"Gut"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-19-3015","article-title":"Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance","volume":"26","author":"Greytak","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1373\/clinchem.2018.298323","article-title":"Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA","volume":"65","author":"Meddeb","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jmoldx.2020.05.006","article-title":"Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis","volume":"22","author":"Gerber","year":"2020","journal-title":"J. Mol. Diagn."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2766\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:19Z","timestamp":1787732359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":63,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172766"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172766","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}